3 completed, 1 not yet recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 3, Not yet recruiting 1 |
Follow BI 456906: new trials by email Literature Review of BI 456906 trials Research Report on BI 456906
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease Survodutide (BI 456906), Placebo - Chronic Kidney Disease | Phase 2 | Not yet recruiting | University Medical Center Groningen | 120 | 2026-03-02 | 2025-10-03 |
| A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) Survodutide, Placebo - Non-alcoholic Steatohepatitis (NASH) | Phase 2 | Completed | Boehringer Ingelheim | 295 | 2021-04-27 | 2024-12-03 |
| A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight BI 456906, Placebo - Obesity | Phase 2 | Completed | Boehringer Ingelheim | 387 | 2021-03-08 | 2023-11-02 |
| A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes. BI 456906, Placebo, Semaglutide - Diabetes Mellitus, Type 2 | Phase 2 | Completed | Boehringer Ingelheim | 413 | 2020-04-30 | 2022-11-29 |
Diabetes Mellitus, Type 2 (1) · Non-alcoholic Fatty Liver Disease (1) · Obesity (1) · Renal Insufficiency, Chronic (1)
Boehringer Ingelheim (3) · University Medical Center Groningen (1)
Australia (3) · Canada (3) · Germany (3) · New Zealand (3) · Poland (3) · South Korea (3) · United Kingdom (3) · United States (3) · Austria (2) · Belgium (2) · China (2) · Czechia (2) · Hungary (2) · Netherlands (2) · Spain (2)
PMID 42331726, PMID 38095657, PMID 38330987, PMID 38847460, PMID 39821928
2019 (1), 2025 (1)